Elrexfio
What Elrexfio is used for
Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Elrexfio
- Active substance
- elranatamab
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Elrexfio
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elrexfio used for?
Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
What is the active substance in Elrexfio?
Elrexfio contains elranatamab.
Who makes Elrexfio?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU